Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.90

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $36.90.

A number of research analysts have recently weighed in on the company. Stifel Nicolaus lifted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a report on Monday, October 14th. JPMorgan Chase & Co. lifted their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an "overweight" rating in a research note on Thursday, November 21st. Citigroup increased their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, November 19th. StockNews.com downgraded shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 23rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new position in Syndax Pharmaceuticals during the 2nd quarter worth $27,000. Values First Advisors Inc. acquired a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $30,000. nVerses Capital LLC bought a new stake in Syndax Pharmaceuticals during the 2nd quarter valued at approximately $33,000. Quantbot Technologies LP acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after buying an additional 541 shares during the last quarter.

Syndax Pharmaceuticals Trading Down 1.2 %

SNDX stock traded down $0.16 during mid-day trading on Friday, reaching $12.77. 2,309,122 shares of the stock traded hands, compared to its average volume of 1,285,349. Syndax Pharmaceuticals has a 52-week low of $12.52 and a 52-week high of $25.34. The stock's fifty day moving average is $16.62 and its 200-day moving average is $19.02. The company has a market cap of $1.09 billion, a P/E ratio of -3.52 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the firm earned ($0.73) EPS. Equities research analysts expect that Syndax Pharmaceuticals will post -2.39 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).